Gilead Sciences experienced positive intraday momentum today, driven primarily by a significant business development announcement in its oncology pipeline. The biopharmaceutical leader entered into an exclusive collaboration and licensing agreement with Vir Biotechnology to discover and advance next-generation, dual-masked T-cell engagers targeting solid tumors. This strategic partnership expands Gilead’s footprint in solid tumor therapeutics while mitigating potential toxicity challenges typical of T-cell engager therapies. Investors reacted favorably to the deal, viewing it as a high-upside expansion of the company’s oncology franchise that complements its established commercial offerings.

Market sentiment was further bolstered by…